Table 1.

Clinical, pathological, and radiological data of the patients

Characteristic	All patients	pCR	N-pCR	p value
Sex
Male	18 (60%)	5 (100%)	13 (52%)	0.066
Female	12 (40%)	0 (0%)	12 (48%)
Age at diagnosis (y)	54 (22, 75)	67 (52, 75)	52 (22, 72)	0.037*
Size	10.71 ± 4.26 (cm)	10.10 ± 2.46 (cm)	10.84 ± 4.57 (cm)	0.731
Location
Upper limb	4 (13.3%)	0 (0%)	4 (16%)	0.373
Lower limb	18 (60%)	3 (60%)	15 (60%)
Trunk	8 (26.7%)	2 (40%)	6 (24%)
T stage
1	3 (10%)	0 (0%)	3 (12%)	0.867
2	9 (30%)	2 (40%)	7 (28%)
3	14 (46.7%)	3 (60%)	11 (44%)
4	4 (13.3%)	0 (0%)	4 (16%)
Grade
GX	3 (10%)	0 (0%)	3 (12%)	0.211
G1	2 (6.6%)	0 (0%)	2 (8%)
G2	14 (46.7%)	2 (40%)	12 (48%)
G3	11 (36.7%)	3 (60%)	8 (32%)
AJCC stage
I	5 (16.7%)	0 (0%)	5 (20%)	0.487
II	0 (0%)	0 (0%)	0 (0%)
III	25 (83.3%)	5 (100%)	20 (80%)
Histology
Liposarcoma/myxoid liposarcoma	11 (36.7%)	2 (40%)	9 (36%)	0.76
Fibrosarcoma/Myxofibrosarcoma	8 (26.7%)	0 (0%)	8 (32%)
Undifferentiated pleomorphic sarcoma	4 (13.3%)	2 (40%)	2 (8%)
Inflammatory myofibroblastoma	2 (6.6%)	0 (0%)	2 (8%)
Other sarcomas	5 (16.7%)	1 (20%)	4 (16%)
Margin status post-operation
Negative	27 (90%)	5 (100%)	22 (88%)	1.00
Positive	3 (10%)	0 (0%)	3 (12%)
Treatment
Radiotherapy + anlotinib	19 (63.3%)	3 (60%)	16 (64%)	0.978
Radiotherapy + apatinib	8 (26.7%)	2 (40%)	6 (24%)
Radiotherapy	3 (10%)	0 (0%)	3 (12%)
Clinical efficacy as per RECIST 1.1
PR	13 (43.3%)	2 (40%)	11 (44%)	0.889
SD	17 (56.7%)	3 (60%)	14 (56%)

Other sarcomas included pleomorphic rhabdomyosarcoma, round cell sarcoma, epithelioid sarcoma, myofibroblastoma, and synovial sarcoma. Grading was performed according to the French Federation of Cancer Centers Sarcoma Group (FNCLCC). AJCC, American Joint Committee on Cancer; RECIST 1.1, Response Evaluation Criteria in Solid Tumors version 1.1. *p < 0.05